Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The company reported a modest beat in Q4 and in-line 2025 revenue guidance, the analyst tells investors in a research note. The firm says Vertex’s pipeline updates were largely incremental, with multiple Phase 1 and 2 data expected in 2025.